Abstract Involvement of matrix metalloproteinases (MMPs) in the pathogenesis of urothelial carcinoma elects them to be sensitive marker for clinical and prognostic implications. MMPs regulate tumor growth and invasion by inducing epithelial-to-mesenchymal transition (EMT) which is characterized by the complex reprogramming of epithelial cells and ultimately bring about major changes in the structural organization of bladder urothelium. The present study has been undertaken to evaluate the clinical relevance of MMPs in two distinct types of bladder cancer disease. Expression analysis of MMPs namely MMP-2, MMP-7, MMP-9 and EMT markers including epithelial marker, E-cadherin; mesenchymal markers, N-cadherin and Vimentin; and EMT-activating transcriptional factors (EMT-ATFs), Snail, Slug, Twist and Zeb was done in 64 cases of bladder tumor tissues [{Non-muscle invasive bladder cancer (NMIBC): 35 cases} and {Muscle invasive bladder cancer (MIBC): 29 cases}] by real-time quantit a t i v e p o l y m e r a s e c h a i n r e a c t i o n ( RT-q P C R ) . Immunohistochemistry (IHC) staining was done in matched bladder tumor tissues to evaluate the protein expression and localization of E-cadherin, N-cadherin, Vimentin, Snail, and Slug. Our data showed overexpression of MMP-2, MMP-7 and MMP-9 at transcriptome level in 32.8%, 25% and 37.5% bladder tumor cases respectively. These tumor tissues were examined for higher expression of mesenchymal markers (Ncadherin and Vimentin) at mRNA and protein level and exhibited statistical association with tumor stage and tumor grade (p = 0.02, p = 0.04, Mann-Whitney test). Significant statistical correlation in tumor tissues with overexpressed MMPs has also been observed between gain of transcriptional factors and weak expression of E-cadherin with tumor stage, grade, gender, presence of hematuria and smoking history of the patients. Gene expression patterns of EMT markers in bladder tumors with overexpressed MMPs and their significant association with clinical profile validate the important role of MMPs in the pathogenesis of urothelial carcinoma of bladder (UCB). Increased expression of specific MMPs may affect several downstream EMT programs and thus may improve its diagnostic and prognostic utility in clinical setting.
Introduction
Urinary bladder cancer is the second most common cause of genitourinary cancer-related deaths worldwide [1] . Surgical resection, adjuvant and neo-adjuvant therapies are commonly employed strategies to fight cancer. These approaches have been successfully accepted in patients with low risk non muscle invasive cancer and locally advanced cancer. Nevertheless, patients with high risk muscle invasive cancers fail to achieve complete pathologic response rates following various treatment modalities [2] . Owing to heterogeneous clinical outcomes and lack of novel strategies that can overcome therapeutic resistance, intense investigation of tumors by their molecular profile and their functions in tumor progression is required.
Protein degrading enzymes/ proteases are extremely important signaling molecules and their dysregulated protease activity leads to not only cancer pathologies but also osteoporosis; cardiovascular and inflammatory diseases; and neurological disorders [3] . Matrix metalloproteinases (MMPs)/ proteases consist of Zn 2+ dependent endopeptidases, participate in the degradation of extracellular matrix (ECM) and thereby create disturbances in ECM regulation which is a prerequisite for unregulated tumor growth, local invasion and metastasis [4] . Expression, secretion of MMP-2 by the stromal cells like fibroblasts and its binding to specific docking sites of nearby tumor cells mark cancer cells for ECM degradation and enable invasive bladder tumor growth [5] . Despite series of encouraging preclinical trials in different cancer models, several small-molecule drugs targeting proteases have been found to be inefficient against advanced stage tumors [3] .
Higher expression of MMPs with ECM-degrading functions is detected in bladder cancer tissue and is associated with high risk of disease progression and recurrence [6] . Their involvement in early stages of bladder carcinogenesis by regulating differentiation, angiogenesis, apoptosis and tumor growth has been reported [7] . Increased proteolytic activity of MMPs including MMP-7 and MMP-9, classified as matrilysins and gelatinases respectively, cleaves, liberates biologically active basement membrane fragments including extracellular domain of E-cadherin from the cell surface, impairs epithelial cell adhesion, reorganizes surrounding ECM, enhances cell motility and promotes tumor cell invasion via aberrant induction of Epithelial-to-mesenchymal transition (EMT) [8] [9] [10] .
EMT is characterized by the complex reprogramming of epithelial cells which includes loss of epithelial cell properties, gain of cell motility and mesenchymal phenotype, increased invasion of tumor cells to surrounding tissues and their metastatic dissemination [11] . Loss of epithelial marker (Ecadherin); gain of mesenchymal markers including Ncadherin and Vimentin; and high expression of EMTactivating transcription factors (EMT-ATFs) define the EMT state of tumors of epithelial origin including urinary bladder cancer [12, 13] . Involvement of EMT and Neutrophil gelatinase-associated lipocalin (NGAL)/ MMP-9 complex as a part of tumor microenvironment has been examined in bladder cancer development and its progression. Identification of conserved, 23-25 nucleotides long, non-coding specific microRNAs (miRNAs) associated with EMT pathway and NGAL/ MMP-9 complex to predict the development of bladder cancer at early stage further validates its important role as diagnostic markers in bladder cancer [14, 15] . In extension to this, another study by Rao et al. examines an alternative new therapeutic approach which employs the use of either estrogen receptor β (ERβ)-siRNA, ERβ antagonist PHTPP, or CCR2 antagonist to interrupt ERβ induced CCL2/CCR2/EMT/ MMP-9 pathway in order to reverse the mast cell-enhanced bladder cancer cells' invasion [16] .
Recent studies document MMPs as the biomarkers for predicting outcomes of bladder cancer. Meta-analysis has been done to evaluate prognostic significance of high MMPs expression; nevertheless, correlation between bladder tumor progression/ metastasis and overexpression of MMPs is still debatable [17] . Enhanced migratory and invasive capacity of MMPs and their involvement in neoplastic transformation, probably through aberrant downstream activation of EMT, makes them an ideal candidate to evaluate their diagnostic and prognostic relevance in two distinct types of bladder cancer disease [18] . The objective of the current study is to examine the downstream activation of EMT programs as a consequence of increased expression of specific MMPs and their clinical utility in early stages of bladder carcinogenesis and tumor invasion.
Materials and Methods

Patients and Tissue Specimens
A total of 64 frozen tissue samples or formalin fixed and paraffin embedded tissue samples of urothelial carcinoma of bladder (UCB) were obtained from Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, India during 2014-2016. Ethical clearance was obtained from Bioethics Cell, Institutional Ethics Committee (IEC), SGPGIMS, Lucknow (Reference no. 2014-166-CP-80) and research was performed on humans in compliance with the Helsinki Declaration. All bladder tumor tissue specimens were of TCC (Transitional cell carcinoma) and included 35 NMIBC (stage pTa-pT1) and 29 MIBC (stage pT2-pT4) types. Cases included tumor samples from patients who underwent transurethral resection of the bladder (TURB, 54 cases) or radical cystectomy (10 cases). Ten tissue specimens as normal tissues were collected from patients with BPH (benign prostate hyperplasia) who had undergone cold cup biopsy of normal bladder mucosa. A small fraction of the excised tumor or normal tissue was surgically resected, immersed in RNA later solution (Ambion; Thermo Fisher Scientific Life Sciences, Waltham, MA), and stored at -80°C until further use. The histological diagnoses of the tumor tissues were done independently by pathologists according to WHO-ISUP, 2004 classification criteria [19] . The clinicopathological profiles of the patients included in the study are summarized in Table 1 .
RNA Extraction and Real Time -Quantitative Polymerase Chain Reaction (RT-PCR) for Quantitative Evaluation of MMP and EMT Markers' Expression at Transcriptome Level
Total cellular RNA extraction was done from frozen tumor and control tissue samples using 1 ml Trizol reagent (Ambion; Thermo Fisher Scientific Life Sciences) and quantified by measuring the absorbance at 260 nm and purity at absorbance of 260/280.cDNA synthesis was done with 1 μg of RNA using the verso cDNA synthesis kit (Thermo Fisher Scientific Life Sciences) according to the manufacturer's instructions. Subsequently, 10 ng of cDNA was subjected to real-time quantitative polymerase chain reaction (RT-qPCR) in 5 μl reaction mix. RT-qPCR was performed in a Quant Studio 7 Flex Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific Life Sciences) using Light Cycler 480 Syber green I master mix (TaKaRa, Clontech) with gene-specific primers mentioned in Table 2 . The cycling conditions for RT-qPCR were initial denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 56°C for 30 s and extension at 72°C for 1 min, and final extension at 72°C for 10 min. The relative levels of mRNA expression were quantified as ΔCt values,by comparing it with the mean Ct values of β-actin taken as reference/endogenous control gene (ΔCt = Ct targetCt reference )to normalize the possible differences in the amount of total RNA. Furthermore, ΔΔCt for the target gene in tumor sample was calculated using ΔCt of normal tissue (ΔΔCt = ΔCt tumor -ΔCt normal ). Average fold change expression was then calculated by 2^-ΔΔCt. Ct values against all the genes were analyzed in triplicates.
Immunohistochemical (IHC) Staining
The immunohistochemical staining for EMT markers was performed using Ultra Vision Quanto detection system, horseradish peroxidase diaminobenzidine (Thermo Fisher Scientific Life Sciences), according to the manufacturer 's instructions.Primary antibodies used in the study include . Three micron thick formalin fixed and paraffin embedded tumor tissue was taken on poly-L-lysine coated glass slides and fixed at 70°C for 3 h. The tissue sections were dewaxed using xylene and then washed with 100%, 70%, 50%, and 20% alcohol for 5 min each followed by washing in running water for 5 min. The slides were then subjected to antigen retrieval with citrate buffer [low pH (citrate) buffer or high pH (Tris ethylene diamine tetra acetic acid) buffer] in antigen retrieval system for 2 cycles of 15 min at 98°C depending on the type of antibody. Sections were washed after blocking the activity of endogenous peroxidase by 3% hydrogen peroxide in methanol for 30 min. Following the treatment of sections with 2-3 drops of skimmed milk, the tissue sections were incubated with the primary antibodies for either 1 h at room temperature or refrigerated temperature for overnight and then incubated with a secondary antibody (amplifier) for 10 min at room temperature. The signals were detected by adding hydrogen peroxide and diaminobenzidine as substrate and chromogen, respectively, followed by counterstaining with Mayers' hematoxylin for 1 min. The slides were mounted in dibutyl phthalate xylene (DPX) medium and visualized for the appearance of brown reaction product. Evaluation of immunohistochemical markers for their localization and expression was done using a Nikon Eclipse 50i light microscope (Nikon, Tokyo, Japan). A total of 1000 cells were counted in consecutive fields at a magnification of 400X. Immunoreactivity of the tumor tissue was analyzed as strong, weak, novel, or no expression. Marker protein was studied for their membranous, nuclear, or cytoplasmic localization. The staining intensity was also assessed in the scale of 0 as no expression, 1 as weak expression, 2 as moderate expression and 3 as strong expression. The overall IHC score was calculated by multiplying the % positive cells and its staining intensity. IHC score of 201-300 was taken as strong expression and below 200 was taken as weak expression in the case of Ecadherin, Snail and Slug. However, IHC score of 0 was taken as no expression and IHC score of >1 was considered as novel expression in case of N-cadherin and Vimentin.
Statistical Tests
Quantitative expression of MMPs and EMT markers at transcriptome level was statistically correlated with pathological features including tumor stage, tumor grade, recurrence, clinical features like smoking and presence of hematuria and non-clinical parameters including gender and age using non-parametric Mann-Whitney U test and one sample t-test. Immunohistochemical evaluation of EMT marker expression and their correlation studies with clinicopathological profile was done using Fisher's exact probability test or chi square test (SPSS version 16.0 software, Microsoft, Redmond, WA). Quantitative data are presented as the mean ± standard error of the mean. The p values less than 0.05 were considered statistically significant.
Results
Clinicopathological Characteristics
Total of 64 patients with UCB and a cohort of 10 cases of normal bladder were included in the current study (Table 1) . Among 64 patients, 93.7% (60/64,) were male patients. A total of 82.8% patients (53/64) were presented with gross total hematuria as the primary clinical symptom during diagnosis. Smoking history was known in 52 patients; out of which 63.4% (33/52) were smokers and 36.5% (19/52) were non-smokers. Of the total patients involved in study, 84.4% (54/64) underwent TURB procedure while 15.6% (10/64) underwent radical cystectomy due to high-risk tumor progression. Histological tumor staging and grading was determined on the biopsies or resected tumor tissues according to WHO-ISUP, 2004 criterion. Of 64 cases, 54.6% (35/64) were classified as NMIBC (stage pTa-pT1) and 45.4% (29/64) were staged as MIBC (stage pT2-pT4). Further, 28.1% (18/64) tumors were classified as low grade and 71.9% (46/64) were presented as high grade. Among 64 cases studied, 47% (30/64) exhibited recurrence over a mean period of fourteen months after initial diagnosis. Metastasis and lymph node involvement was observed in 10.9% (7/64) patients over a mean period of 42 months since their initial diagnosis of bladder tumor.
Expression Analysis of MMPs in Tumor Tissues of Urothelial Carcinoma and their Involvement with EMT Cascade
The mRNA expression of MMPs including, MMP-2, MMP-7 and MMP-9 and EMT markers including epithelial marker, Ecadherin; mesenchymal markers, N-cadherin and Vimentin; and EMT-activating transcriptional factors, Snail, Slug, Twist and Zeb was examined in 64 bladder tumor specimens. Ten normal bladder tissue specimens were also examined for gene expression by RT-qPCR and treated as control to calculate the fold change in expression of the given markers in tumor tissues (Fig. 1a-f) . IHC was done to check the protein expression and localization of E-cadherin, N-cadherin and (Fig. 1a, b (4/21) showed weak expression of E-cadherin, 85.7% (18/21) showed increased expression of mesenchymal markers and 17/ 21 (80.9%) showed an increased expression of EMT-ATFs. Among tumors with overexpressed MMP-2, 16.6% (3/18) and 11.7% (2/17) metastatic tumors showed increased expression of mesenchymal markers and transcriptional factors respectively.Significant statistical correlation was observed between the expression of MMP-2 and gain of mesenchymal markers (N-cadherin + Vimentin) with low stage (p = 0.02, Mann-Whitney test). Significant association was also observed between increased MMP-2 expression and gain of EMT-ATFs (Snail + Slug + Twist + Zeb) with the presence of hematuria (p = 0.04, Mann-Whitney test) ( Table 3) . IHC results in tumors with higher MMP-2 levels showed weak expression of Ecadherin in 23.8% (5/21) tumors, however, 19% (4/21) showed novel expression of mesenchymal markersand 33.3% (7/21) showed an increased expression of Snail and Slug (Table 3 Tumors showing increased expression of EMT-ATFs (Snail and Slug) were assessed for statistical significance with tumor high stage (p = 0.04, Mann-Whitney test) and smoking (p = 0.001, One sample T-test) ( Table 3) .
Clinical Relevance of MMP-7 and EMT Cascade
Higher expression of MMP-7 at transcriptome level was reported in 25% (16/64) bladder tumor cases, out of which 81.25% (13/16) were identified as high grade and 43.75% (7/16) were examined as high stage (Fig. 1a, b) (Table 4) . Immunohistochemical analysis revealed weak expression of E-cadherin in 18.8% (3/16) cases, novel expression of mesenchymal markers (N-cadherin + Vimentin) in 18.8% (3/16) cases while upregulated expression of EMT-ATFs (Snail + Slug) in 31.2% (5/16) tumors (Figs. 2 and 3 ). These tumor tissues were examined for statistical significance for gain of EMT-ATFs with tumor high grade (p = 0.001, One sample Ttest), smoking (p = 0.001, Mann-Whitney test) and presence of hematuria (p = 0.001, One sample T-test) ( Table 7) .
Clinical Relevance of MMP-9 and EMT Cascade
Higher expression of MMP-9 through RT-qPCR at transcriptome level was reported in 37.5% (24/64) cases, out of which 75% (18/24) were of high grade and 41.7% (10/24) were examined as high stage (Fig. 1 a and (Table 5 ). Among tumors with higher levels of MMP-9, 15% (3/20) and 14.2% (3/21) metastatic tumors showed increased expression of mesenchymal markers and transcriptional factors respectively.
Immunohistochemical analysis was done in 24 cases which were observed for increased expression of MMP-9. IHC analysis in 24 cases with higher levels of MMP-9 revealed focal loss of membranous E-cadherin in 25% (6/24) cases, while 16.7% (4/24) and 29.2% (7/24) cases showed novel membranous expression of mesenchymal markers (N-cadherin + Vimentin)and nuclear expression of EMT-ATFs (Snail + Slug) respectively in invasive front of budding tumor areas (Figs. 2 and 3 
Discussion
Critical involvement of MMPs in tumor-supporting cellular processes including loss of cell adhesion, ECM degradation and EMT reveal their potential role as markers of clinical significance in different stages of disease course. EMT is characterized by loss of cell adhesion, enhanced cell motility and invasive tumor growth. Differences in EMT related programming could be one of the possible reasons for the observed differences in disease progression of two distinct bladder cancer types [13, 20] . The present study has been undertaken to examine the downstream activation of EMT programs as a consequence of enhanced expression of specific MMPs and their clinical relevance in a subset of bladder tumors. The current study involves assessment of levels of MMPs (MMP-2, MMP-7 and MMP-9) and panel of EMT markers (E-cadherin, N-cadherin, Vimentin and EMT-ATFs) by RTqPCR at transcriptome level. IHC was done to quantitatively localize the protein expression of EMT markers (E-cadherin, N-cadherin, Vimentin, Snail and Slug). The results of the experiments/ expression of marker genes were statistically correlated with clinical and pathological features in two distinct types of bladder cancer disease namely NMIBC and MIBC. Growth factors and cytokines regulate the expression of MMP-2. High levels of MMP-2 facilitate its binding to the docking sites of nearby tumor cells, mark them for the degradation of ECM thus enable invasive tumor growth and correlate with metastatic bladder cancer phenotype. Research studies report the predominant localization of MMP-2, its high activity, enhanced expressions and correlation with poor prognosis (high tumor stage and grade) in bladder tumor cells and clearly indicate its role in metastatic bladder cancer phenotype [5, [21] [22] [23] [24] . Increased migration ability and tumor invasion has been associated with higher expression of MMP-2 and EMT phenotype in bladder cancer cell lines [25, 26] [5, 21, 23, 27 ]. In the current study, high expression of MMPs examined by RT-qPCR demonstrates its relationship with focal loss of E-cadherin, gain of mesenchymal markers and increased levels of EMT-ATFs in tumor tissues in concordance with earlier studies indicate important role of MMP-2 in impairing epithelial cell adhesion, and promoting tumor cell invasion via activating EMT program [8, 26, 28] . Significant correlation of EMT-associated markers in MMP-2 overexpressed tumors with tumor stage, grade, age gender, smoking and hematuria confirm the diagnostic and prognostic utility of markers. MMP-7, smallest member of MMP family with wide substrate specificity, has been known to be involved in E-cadherin and Fas receptor cleavage thus disrupts cell-cell interaction, inhibits apoptosis, induces EMT and plays versatile role in tumor metastasis [8, 29] . Its involvement in the development of chemotherapy resistance further enhances its utility as a marker of therapeutic importance. Despite the differences in sample collection methods, type of biological specimen (tissue, urine, serum) and method of analysis in independent patient cohort, elevated MMP-7 levels has been observed to be significantly related with lymph node metastasis and clearly proved to be an unfavorable prognostic factor for metastasis free bladder cancer disease [30] . Study by Svatek et al. determined the clinical relevance of high levels of circulating MMP-2 using a particle-based flow cytometric assay in plasma samples from patients with bladder cancer [31] . Present study analyses the reduced expression of membranous Ecadherin; novel membranous expression of N-cadherin and Vimentin; enhanced nuclear expression of Snail and Slug through IHC in in tumors with overexpressed MMP-7 Several growth factors, cytokines (interferon-γ, epidermal growth factor, tumor necrosis factor), embryonic stem cell markers (Oct-3/4) are shown to increase MMP-9 expression and thus enhanced invasion and metastatic potential in urinary bladder cancer cells in experimental setting [32] [33] [34] [35] . Further, central role of MMP-9 in decreased cell adhesion capacity and enhanced cell motility via inducing EMT has been linked with bladder cancer progression [7, 36] . Current study demonstrates the clinical association of MMP-9 with high tumor stage, grade, sex, presence of hematuria and smoking status. EMT-associated markers in tumors with over expressed MMP-9 showed significant correlation with tumor high grade, gender and hematuria. 
Conclusions
Complex functions of distinct MMPs in various tumor supporting cellular processes mark them an important clinical 
